BlueSphere Bio to Present a Corporate Overview at the 2022 BIO International Convention
PITTSBURGH, PA, June 13, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that David Apelian, M.D., Ph.D., MBA, Chief Executive Officer of BlueSphere Bio, will provide a corporate overview at the 2022 …
BlueSphere Bio to Present a Corporate Overview at the 2022 BIO International Convention Read More »